- Conditions
- Dent Disease
- Interventions
- Genetic Analysis
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 575
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Hepatitis C
- Interventions
- Peginterferon, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Interventions
- Comprehensive medication management with PGx testing results, Usual Care
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Hepatitis C
- Interventions
- SCV-07
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 16
- States / cities
- Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more
- Conditions
- Hepatitis C Infection
- Interventions
- Placebo, SCY-635, Pegasys, Copegus
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- San Francisco, California • Durham, North Carolina • San Antonio, Texas
- Conditions
- Hepatitis C
- Interventions
- Sofosbuvir, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Bakersfield, California + 55 more
- Conditions
- Alzheimer's Disease
- Interventions
- BOLD and Perfusion brain MRI
- Procedure
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer
- Interventions
- Oxaliplatin, Leucovorin Calcium, Irinotecan Hydrochloride, Fluorouracil, Conventional Surgery
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Cystic Fibrosis
- Interventions
- ivacaftor, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Major Depressive Disorder
- Interventions
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Genetic · Other
- Lead sponsor
- Genomind, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
- Conditions
- Genetic Predisposition, Type2diabetes
- Interventions
- Exendin 9-39, Saline
- Biological · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, Tolbutamide Inhibition - Tolbutamide & Fluconazole
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hepatitis C
- Interventions
- SOF, VEL, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 50
- States / cities
- La Jolla, California • Long Beach, California • Los Angeles, California + 38 more
- Conditions
- Substance Abuse
- Interventions
- Not listed
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bloodstream Infection
- Interventions
- Accelerate PhenoTest™ BC kit, Standard of Care
- Diagnostic Test
- Lead sponsor
- Accelerate Diagnostics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
- Interventions
- Alvelestat (MPH966), Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 7 more
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7,776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2009
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana + 4 more
- Conditions
- Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma, Gastric Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IV Ampulla of Vater Cancer, Stage IV Gallbladder Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer
- Interventions
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Leucovorin Calcium, Irinotecan Hydrochloride, Fluorouracil, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
- Conditions
- Healthy, Alcohol Consumption
- Interventions
- PHEN feedback, PHEN+GENE Feedback, Control
- Behavioral · Genetic · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 17 Years to 25 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
- Interventions
- Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Genotype 1 Chronic Hepatitis C, Treatment Naive
- Interventions
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 34 more
- Conditions
- Chronic Hepatitis C
- Interventions
- SOF, RBV, Placebo to match SOF, Placebo to match RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 51
- States / cities
- Coronado, California • Los Angeles, California • San Diego, California + 41 more
- Conditions
- Hepatitis C
- Interventions
- Ribavirin, Mericitabine, Peginterferon Alfa-2a, Placebo, Telaprevir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more
- Conditions
- Hepatitis C
- Interventions
- DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
- Drug
- Lead sponsor
- Timothy Morgan, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Long Beach, California